Skip to main content

Hédia Marrakchi

Hedia Marrakchi obtained her PhD in Biochemistry in 2000 working in the lab of Dr Mamadou Daffé and Prof. Gilbert Lanéelle (under the supervision of Dr A. Quémard) on the biosynthesis of mycolic acids, specific lipids of mycobacteria and major constituents of their outer membrane. She notably characterized enzymes of the pathway, targets of the antintuberculous drug isoniazid. She joined for her postdoctoral fellowship the lab of Dr Charles O. Rock at the St Jude Children’s Research Hospital (Memphis, Tennessee) where she developed transcriptomic tools to investigate the role of enzymes involved the synthesis and regulation of bacterial fatty acids. Back to France, she joined (2003-2004) the group of Dr Frédéric Altare as a research associate at the CNRS where she developed a dedicated DNA chip "granulochip" to study expression of host genes in response to different mycobacteria in the in vitro human granuloma model. She was recruited (2004) as a senior research associate at the CNRS in the group of Dr Mamadou Daffé where she pursued her interest in biochemical characterization of many enzymes of the lipid metabolic pathways as relevant anti-tuberculous targets. She has participated to European-funded consortia dedicated to anti-TB drug development (New Medicines for TB (NM4TB), Systems Biology of Mtb (SysteMTb)), and is actively involved in collaborative programs for the development of strategies aiming at anti-bacterial drug discovery. She built on a tight collaboration with the industrial partner AstraZeneca (AZ) for development of biochemical assays adapted to High Throughput Screening, thus achieving screening campaigns on mycobacterial targets (AZ and on-site with PICT).
These research activities have generated 22 original articles and reviews, 3 book chapters and 1 patent.